Explore

Rapid Read Rapid Read
Vast Therapeutics Unveils Promising Phase 1 Data for ALX1 Inhaled Therapy at ATS 2026

Vast Therapeutics Unveils Promising Phase 1 Data for ALX1 Inhaled Therapy at ATS 2026

Vast Therapeutics, a clinical-stage life science company, has presented late-breaking Phase 1 data for its inhaled drug candidate ALX1 at the American Thoracic Society (ATS) 2026 International Conference in Orlando, Florida. The data revealed that ALX1, a first-in-class nitric oxide prodrug, was well tolerated in healthy volunteers, with no dose-limiting toxicities observed. The study demonstrated systemic dose-proportional pharmacokinetics, supporting further clinical development in muco-obstructive airway diseases such as bronchiectasis and COPD. The therapy aims to deliver sustained release nitric oxide in the lungs, addressing both inflammatory and microbial drivers of disease progression without toxicity.
Trendline Trendline
MSD's Sac-TMT Shows Promise in Phase 3 Endometrial Cancer Trial

MSD's Sac-TMT Shows Promise in Phase 3 Endometrial Cancer Trial

MSD's Sac-TMT Shows Promise in Phase 3 Endometrial Cancer Trial
Trendline Trendline
Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support

Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support

Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support
Trendline Trendline
Tiziana Life Sciences Reports Positive Data for Intranasal Foralumab in Multiple Sclerosis Treatment

Tiziana Life Sciences Reports Positive Data for Intranasal Foralumab in Multiple Sclerosis Treatment

Tiziana Life Sciences Reports Positive Data for Intranasal Foralumab in Multiple Sclerosis Treatment
Trendline Trendline
CEL-SCI Reports Progress in Multikine Cancer Therapy Development

CEL-SCI Reports Progress in Multikine Cancer Therapy Development

CEL-SCI Reports Progress in Multikine Cancer Therapy Development
Trendline Trendline
Sumitomo Pharma America Presents Promising Vibegron Data for Older Men with Overactive Bladder

Sumitomo Pharma America Presents Promising Vibegron Data for Older Men with Overactive Bladder

Sumitomo Pharma America Presents Promising Vibegron Data for Older Men with Overactive Bladder
Trendline Trendline
Regeneron's Fianlimab Fails Phase 3 Trial in Melanoma, Impacting Future Prospects

Regeneron's Fianlimab Fails Phase 3 Trial in Melanoma, Impacting Future Prospects

Regeneron's Fianlimab Fails Phase 3 Trial in Melanoma, Impacting Future Prospects
Trendline Trendline
CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results
Rapid Read Rapid Read
Amylyx Pharmaceuticals Publishes Phase 2 Trial Data for AMX0035 in Wolfram Syndrome

Amylyx Pharmaceuticals Publishes Phase 2 Trial Data for AMX0035 in Wolfram Syndrome

Amylyx Pharmaceuticals has announced the publication of results from its Phase 2 open-label HELIOS trial in The Journal of Clinical Investigation. The trial evaluated AMX0035, a combination of sodium phenylbutyrate and taurursodiol, in adults with Wolfram syndrome. The study showed improvements in pancreatic beta cell function and glycemic control over 48 weeks, with stabilization in visual acuity. The trial's findings suggest AMX0035's potential to alter the progression of Wolfram syndrome, a rare genetic disorder characterized by diabetes and neurodegeneration. The drug was generally well-tolerated, with no serious adverse events reported.
Trendline Trendline
Amylyx Pharmaceuticals Publishes Phase 2 Trial Data for AMX0035 in Wolfram Syndrome

Amylyx Pharmaceuticals Publishes Phase 2 Trial Data for AMX0035 in Wolfram Syndrome

Amylyx Pharmaceuticals Publishes Phase 2 Trial Data for AMX0035 in Wolfram Syndrome
Trendline Trendline
Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact
Rapid Read Rapid Read
Resmetirom Shows Potential in Combating Liver Cancer Linked to Fatty Liver Disease

Resmetirom Shows Potential in Combating Liver Cancer Linked to Fatty Liver Disease

A recent study has revealed that Resmetirom, a drug approved by the U.S. Food and Drug Administration (FDA) for treating metabolic dysfunction associated fatty liver disease (MAFLD), may also help prevent and suppress liver cancer. Conducted by researchers from the University of Hong Kong, the study found that Resmetirom not only reduces liver fat but also slows tumor growth and lowers levels of the Midkine (MDK) protein, which is linked to cancer progression. The study highlights the potential of Resmetirom in reshaping the immune microenvironment and improving liver metabolism, suggesting its clinical value in future treatment strategies for liver cancer.